Evidence map›Paper›PMID 35777198›Full record

ArticleRedox biology2022

Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction.

Han Li, Jing Zhu, Yan-Wu Xu, Fang-Fang Mou, Xiao-Li Shan, Qiang-Li Wang, Bao-Nian Liu, Ke Ning, Jia-Jia Liu, Ya-Chao Wang and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety ofFrontiers in pharmacology · 2024
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Han LiAcademy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jing ZhuDepartment of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yan-Wu XuDepartment of Biochemistry, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Fang-Fang MouDepartment of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Xiao-Li ShanSchool of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Qiang-Li WangDepartment of Histoembryology, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Bao-Nian LiuDepartment of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Ke NingDepartment of Physiology, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jia-Jia LiuAcademy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Ya-Chao WangAcademy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jin-Xia MiScience and Technology Center, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaohui WeiThe MOE Key Laboratory for Standardization of Chinese Medicines and the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Shui-Jin ShaoDepartment of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Guo-Hong CuiDepartment of Neurology, Shanghai No. 9 People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China. Electronic address: gh_cui@qq.com.
Rong LuSchool of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: lurong@shutcm.edu.cn.
Hai-Dong GuoAcademy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Anatomy, School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: hdguo@shutcm.edu.cn.
Shanghai University of Traditional Chinese Medicine · CNRuijin Hospital · CNState Administration of Traditional Chinese Medicine of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Notoginsenoside R1 (NGR1) is the main monomeric component extracted from the dried roots and rhizomes of Panax notoginseng, and exerts pharmacological action against myocardial infarction (MI). Owing to the differences in compound distribution, absorption, and metabolism in vivo, exploring a more effective drug delivery system with a high therapeutic targeting effect is crucial. In the early stages of MI, CD11b-expressing monocytes and neutrophils accumulate at infarct sites. Thus, we designed a mesoporous silica nanoparticle-conjugated CD11b antibody with loaded NGR1 (MSN-NGR1-CD11b antibody), which allowed NGR1 precise targeted delivery to the heart in a noninvasively manner. By increasing targeting to the injured myocardium, intravenous injection of MSN-NGR1-CD11b antibody nanoparticle in MI mice improved cardiac function and angiogenesis, reduced cell apoptosis, and regulate macrophage phenotype and inflammatory factors and chemokines. In order to further explore the mechanism of NGR1 protecting myocardium, cell oxidative stress model and oxygen-glucose deprivation (OGD) model were established. NGR1 protected H9C2 cells and primary cardiomyocytes against oxidative injury induced by H

Indexed as

Myocardial InfarctionNanoparticlesAnimalsApoptosisGinsenosidesGlucoseHydrogen PeroxideMiceMolecular Docking SimulationProto-Oncogene Proteins c-aktSilicon DioxideGinsenosidesGlucoseHydrogen Peroxidenotoginsenoside R1Proto-Oncogene Proteins c-aktSilicon DioxideHippo signaling pathwayMAPK signaling pathwayMesoporous silica nanoparticlesMyocardial infarctionNotoginsenoside R1PI3K/AKT signaling pathwayTargeting

Identifiers

PMID35777198
PMCPMC9287735
OpenAlexW4283373181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.